Summary.-Three hundred and seventy-two patients were randomized between 3 regimens of chemotherapy: cyclophosphamide, intermittent melphalan, and melphalan with prednisone, and were followed up to death or for at least 5 years. There was no difference in survival between the treatments, either overall or in any subgroup of patients. Therefore, the choice among these 3 treatments should be guided by the patient's comfort and convenience.
IN THE Medical Research Council's First Myelomatosis Trial, previously untreated patients were randomly allocated to receive daily oral cyclophosphamide or melphalan. By August 1968, when 276 patients had been entered into the first trial, there was no significant difference in survival between the two groups (MRC, 1971) . During the course of that trial it was claimed by others that intermittent melphalan was more effective than continuous administration, and that the addition of prednisone to intermittent melphalan gave further benefit (Bergsagel et al., 1967; Alexanian et al., 1969) . The MRC's Second Myelomatosis Trial, which 57 we now report, was therefore started to compare cyclophosphamide at the same dosage as in the first trial with a schedule ofintermittent melphalan, and intermittent melphalan with prednisone. The protocols Cyclophosphamide was administered orally at a daily dose of 150 mg or, if neutropenia or thrombocytopenia developed (see below) at the highest tolerated dose.
Intermittent melphalan was administered in a short 4-day course and subsequent 7-day courses. First course: 10 mg daily for 4 days. If the blood urea con-centration (BUC) was over 13 3 mm, treatment was delayed until the patient had been adequately hydrated, and then 5 mg was given daily for 4 days. Second and subsequent courses: 10 mg daily for 7 days or 5 mg daily for 7 days if BUC still exceeded 13 3 mm, reduced to 3-5 days if it considerably exceeded 13 3 mm.
The interval between courses was usually 6-8 weeks, depending on the trends in the neutrophil and platelet counts. Treatment was deferred or reduced if the neutrophil count remained below 2-5 x 109/1 and/or the platelet count remained below 100 x 109/1.
Intermittent melphalan and prednisone. Melphalan was administered intermittently as above, each daily dose being accompanied by 40 (Peto et al., 1976 (Peto et al., . 1977 The immunoglobulins in the serum and urine were estimated in one central laboratory by cellulose-acetate electrophoresis and typed by electrophoresis (Hobbs, 1967) . The radiological findings were abstracted from local skeletal surveys of the skull, axial skeleton and long bones.
RESULTS
In addition to the effects of the 3 treatments on survival, the various presentation features recorded for all 372 patients were considered in relation to prognosis. For those patients on whom the relevant data were available, other features also considered were the serum levels of albumin, IgM, paraprotein and calcium, the paraprotein type and urinary BJP and HMWP concentration.
Effect of treatment on survival
There was no apparent difference in survival between the 3 treatment schedules (X2= 0'09, Fig. 1 ). Overall, the median length of survival was 20 months from the date of randomization.
Renal function
The strongest determinants of prognosis in patients with myelomatosis have been shown to be those indicating renal impairment, namely elevated BUC and excessive amounts of HMWP in the urine. Fig. 2 (x2 = 62.6). This 3-value composite variable will be used in the rest of the analyses to allow for the effect of renal impairment in the assessment ofthe other prognostic features. Anaemia
The relationship between haemoglobin value at presentation and prognosis was highly significant statistically (X2 =21 1).
Much of this was due to the strong correlation of haemoglobin concentration with renal function (Table II) Treatment among patients with normal haemoglobin (> 100 g/l) and good renal function Because of the overriding effect of impaired renal function on prognosis, any real benefits of a treatment which effectively reduced the total tumour-cell mass might be obscured by irreversible renal damage. The apparent lack of difference between the 3 treatments (as shown in Fig. 1 ) might have arisen because real but small differences between the 3 treatments were overshadowed by the effects of renal damage. To discover whether there were treatment differences among patients whose disease was uncomplicated by such features, we have therefore compared the results for the 107 patients with good renal function and haemoglobin level of > 100 g/l. However, there was still no evidence of any material difference between the 3 treatments (Fig. 4) Table III .
Paraproteins
The level of paraprotein in the serum (of patients without BJP myeloma) bore no relationship to prognosis for IgG patients, but among IgA patients there was a nonsignificant tendency for those with higher paraprotein concentrations to die earlier. The observation arising from the 1st MRC trial (1973) that patients whose serum paraprotein level fell slowly during treatment did better than those whose level decreased rapidly, was not confirmed. In the present trial, faster responders fared better than slow responders, and better than those who did not respond at all, though the differences were not statistically significant.
Of Platelet count and the levels of serum albumin and alkaline phosphatase at presentation were independently related to prognosis, to degrees which were statistically significant (x2= 10-7, 12*9 and 329 respectively) but each effect was reduced when adjustment was made for renal function (X2=5 8, 5X5 and 3 l respectively). The only factor which retained significance within a renal-function group was the level of serum albumin in patients with poor renal function. In all 3 renalfunction groups, patients with low platelet counts tended to do worse than the others during the first 12 months of treatment, but thereafter their prognosis was similar. No other prognostic feature was statistically significant when related to prognosis, either overall or for patients with good renal function. Furthermore, there was no subgroup of patients defined by prognostic features measured at presentation where a striking difference could be found in the effects of treatment.
DISCUSSION
The present trial was designed to compare 3 treatment schedules for myelomatosis, but has not demonstrated any difference in length of survival between the groups. Moreover, no difference could be found within the most favourable group of patients: those whose disease was uncomplicated by features, particularly advanced renal failure, that could not be reversed by a reduction of the tumour-cell mass. Treatment with 7-day courses of melphalan at monthly intervals is generally accepted as better tolerated than daily cyclophosphamide, but the addition of prednisone gave no apparent improvement in survival. However, preliminary analysis of the trial suggested that melphalan plus prednisone might be somewhat better, and this influenced the design of the 3rd MRC Myelomatosis Trial (MRC, 1980 ) which compared intermittent highdose cyclophosphamide with intermittent melphalan and prednisone for nonazotaemic patients.
Analysis of the various radiological, biochemical and haematological features measured at presentation confirmed many of the findings of the 1st MRC Myelomatosis Trial. The extent of renal dysfunction, measured by BUC and the concentration of HMWP in the urine as well as by clinical assessment, again proved to be the most important prognostic feature. All other features were less important when allowance was made for renal condition. However, among patients without renal dysfunction, other features such as haemoglobin, urinary BJP, and serum IgM level were useful (though interrelated) indicators of prognosis.
The cause of anaemia in myelomatosis is not known. It may reflect the extent of marrow infiltration by myeloma cells, though the strength of the association of haemoglobin level with longevity in this and in the 3rd trial (MRC, 1980) Table III ). However, when 9 of these were investigated further (the records were missing for 2), 5 were uraemic from infection, severe vomiting and dehydration or longstanding kidney disease, and a further 2 had normal ureas after hydration. In only 2 was there no explanation for the uraemia.
The subnormal concentrations of polyclonal (IgM) immunoglobulins in the serum of myeloma patients are thought to result from a suppressive effect on immunologically active cells exerted by the myeloma cells. The magnitude of the effect might then be expected to be proportional to the total number or activity of myeloma cells, and our finding of a progressive worsening of the prognosis in patients with successively declining serum IgM concentrations is consistent with this.
In the 1st MRC Myelomatosis Trial (MRC, 1973 ) the level of serum albumin was found to be of important and independent prognostic significance. In the present trial it was found to be of much less independent importance. Although there was a fairly strong relationship between albumin level and survival, this was considerably reduced when allowance was made for renal function (Fig. 6) . The remaining effect was in the same direction as in the first trial but was not very substantial. One suggested explanation is that in the first trial the albumin concentrations were all estimated in a single laboratory by a single method, whereas in the present trial each centre performed its own albumin assays and different methods were used. (Some centres used autoimmunoprecipitation (AIP) but others used electrophoresis, which carries the risk that the presence of myeloma protein might bias the estimation of the albumin concentration.) In the 3rd Trial as well (MRC, 1980) no statistically significant relationship between initial albumin and survival remained after adjusting for other features. Consequently, it seems most likely that albumin is less important than we originally believed (MRC, 1973) and that the strength of the correlation of albumin with prognosis which we observed in the 1st Trial was in part an artefact of chance or of incomplete adjustment for other factors.
It is possible to identify a group of patients (those with good renal function and Hb > 100 g/l) comprising almost one third of those in the study, who have a 43% 5-year survival. Perhaps patients in this group should receive more intensive therapy (aimed at disease eradication) since they are more likely to respond to treatment, and renal failure is not an immediate problem for them. Alternatively, if all we can hope for is palliation, patients with good prognosis may need less cytotoxic therapy. In either case, division of patients into 2-3 groups with markedly different prognosis may be of assistance in devising future trials.
